Skip to main content

Stability of oestrogen and progesterone receptor antigenicity in formalin-fixed paraffin-embedded breast cancer tissue over time.

Ehinger A, Bendahl PO, Rydén L, Fernö M, Alkner S

Publication: APMIS (2018) • Vol 126 • Page 746-754PMID: 30160021View on PubMed

Purpose

The purpose of this paper was to evaluate estrogen receptor (ER) and progesterone receptor (PR) immunohistochemical (IHC) staining results after prolonged storage of formalin-fixed, paraffin-embedded (FFPE) archival blocks using a tissue microarray with results of cytosol analysis obtained at the time of diagnosis.  Two additional antigens, human epidermal growth factor receptor 2 (HER2) and Ki-67, were also evaluated in archival FFPE specimens.

Conclusion

Overall concordance between immunohistochemical staining for ER and PR of archival FFPE tumor specimens and cytosol analysis at the time of diagnosis was high for both ER (87% of patients) and PR (86% of patients).  While the authors observed a higher concordance between the two methods for PR among specimens collected after (as opposed to before) 1986, they could not conclude a loss of antigenicity among older specimens since the method of cytosol analysis also changed over the time period examined. No such trend with increasing duration was observed between immunohistochemical and cytosol analysis for ER. The proportion of HER2 positive and Ki-67 high tumors, which are common among ER-negative breast cancer tumors, remained constant over time among both ER-positive and -negative tumor specimens and among PR-positive and PR-negative tumor specimens. 

Studies (1)

Purpose

The purpose of this study was to evaluate immunohistochemical staining in archival FFPE breast cancer tumor specimens and compared results of cytsol analysis obtained at the time of diagnosis.  A tissue microarray containing 1328 tumor specimens from 728 patients diagnosed with contralateral breast cancer was used for the analysis.  ER and/or PR cytosol data at the time of diagnosis (1978-2000) was available for 573 tumor specimens on the array.  Immunohistochemical staining for ER, PR, HER2, and KI-67 was conducted on the archival specimens using an autostainer, and staining was evaluated by a pathologist. A positive status was set at ≥10% stained nuclei for ER and PR and a HercepTest score of 3+ for HER2, while Ki-67 staining was considered as high when >20% of cell nuclei stained positive.  Prior cytosol analysis of ER and PR had been performed on freshly frozen specimens within 8 days of surgical removal using the ligand binding assay, the dextran-coated charcoal method and Scatchard analysis, or an enzyme immunoassay. A positive status for cytosol analysis was set at ≥25 fmol/mg protein.

Summary of Findings

Of the breast cancer tumors represented on the tissue microarray, concordant results of cytosol analysis at the time of diagnosis and recent immunohistochemical staining was obtained for 87% of patients for ER and 86% for PR. Notably, concordance for PR was higher among specimens procured more recently (those collected between 1978-1985 versus those collected between 1986-2000; p=0.005), which may be attributable to a change in cytosol analysis method from ligand binding assay to the enzyme immunoassay or more reliable immunohistochemical results with newer specimens.  No such trend with storage duration was observed between immunohistochemical and cytosol analysis for ER. The proportion of HER2 positive and Ki-67-high tumors, which are common among ER-negative breast cancer tumors, remained constant over time among both ER-positive and -negative tumor specimens and among PR-positive and PR-negative tumor specimens.  The authors also noted that since tumor specimens identified as ER or PR positive by immunohistochemistry, but negative by cytosol analysis, were frequently lobular carcinomas, immunohistochemical analysis may be a superior method of detection for this cancer subtype.

  • Biospecimens

    TissueBreast
  • Preservation Types

    FormalinFrozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    ProteinReceptor binding
    ProteinTissue microarray
    ProteinImmunoassay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    StorageStorage duration
    Up to 40 y
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    Ki-67
    PR
    Receptor binding SpecificTargeted peptide/protein
    ER
    PR
    Immunoassay SpecificTargeted peptide/protein
    ER
    PR